Arbutus Biopharma (ABUS) has released an update.
Arbutus Biopharma is poised for a productive 2024, with plans to release important clinical data from ongoing trials of its hepatitis B treatments, imdusiran and AB-101, and to start a new trial. The company has maintained a strong financial standing with $132M in cash and investments, ensuring operations are funded into the first quarter of 2026. Additionally, a legal dispute with Moderna over lipid nanoparticle technology is set for trial in April 2025.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.
